Drugs / intoplicine
intoplicine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003713 | Aug 1997 → ? | cancer of unknown primary site | Genzyme, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intoplicine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003713 ↗ |
| Known as | Intoplicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908351 ↗ |
| Known as | RP 60475 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908351 ↗ |
| Known as | RP-60475 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908351 ↗ |
| Modality | Small molecule | — CHEMBL1908351 ↗ |
| Route | Intravenous | “intoplicine IV by continuous infusion for 5 days” NCT00003713 ↗ |